Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aarey Drugs & Pharmaceuticals Total Current Liabilities Chart
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.
Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.
What does a Total Current Liabilities of ₹1,451 Mil mean?
Aarey Drugs & Pharmaceuticals (BOM:524412) has a Total Current Liabilities of ₹1,451 Mil as of Mar. 2026. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Aarey Drugs & Pharmaceuticals and its competitors.
Is Aarey Drugs & Pharmaceuticals' Total Current Liabilities too high?
Aarey Drugs & Pharmaceuticals' current Total Current Liabilities is ₹1,451 Mil. Overall, Aarey Drugs & Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aarey Drugs & Pharmaceuticals' Total Current Liabilities compare to ZTS?
Aarey Drugs & Pharmaceuticals' Total Current Liabilities of ₹1,451 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Drug Manufacturers company?
A good Total Current Liabilities depends on the Drug Manufacturers industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Aarey Drugs & Pharmaceuticals and its competitors. Aarey Drugs & Pharmaceuticals's current Total Current Liabilities is ₹1,451 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarey Drugs & Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Aarey Drugs & Pharmaceuticals (BOM:524412) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹58.30, compared to a current price of ₹77.52 — trading 33% above its estimated fair value. The current Total Current Liabilities is ₹1,451 Mil. Aarey Drugs & Pharmaceuticals' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Aarey Drugs & Pharmaceuticals (BOM:524412), the current Total Current Liabilities is ₹1,451 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aarey Drugs & Pharmaceuticals (BOM:524412) Overvalued in 2026?
Based on GuruFocus' analysis, Aarey Drugs & Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹77.52 is trading 33% above its estimated GF Value™ of ₹58.30.
GuruFocus considers Aarey Drugs & Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for BOM:524412:
Total Current Liabilities: ₹1,451 Mil
GF Value™: ₹58.30 vs. price of ₹77.52 (33% above fair value)
No single metric tells the full story. See the BOM:524412 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aarey Drugs & Pharmaceuticals Business Description
Aarey Drugs & Pharmaceuticals Ltd is engaged in bulk drug manufacturing and offers products for industrial applications. The company manufactures active pharmaceutical ingredients, intermediates, and specialty chemicals. It is also involved in the trading of industrial solvents and chemicals. The products offered by the company include N-Methyl urea, Dimethyl urea, Mefenamic acid, Metformin, Doxaphylline, and BMD among others. The company principally carries out its business operations in India.
60GF Score
Get the complete analysis for BOM:524412
Total Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524412 has been successfully added to your 
